News | October 28, 2024
Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Total investment incurred for setting up the new R&D Rs 250 crore
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Morepen Labs successfully raised Rs. 200 Crore through QIP
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
Laurus Labs receives EIR from USFDA for API facilities
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Subscribe To Our Newsletter & Stay Updated
